PL3247791T3 - Uniwersalne komórki nkt - Google Patents

Uniwersalne komórki nkt

Info

Publication number
PL3247791T3
PL3247791T3 PL16701339.0T PL16701339T PL3247791T3 PL 3247791 T3 PL3247791 T3 PL 3247791T3 PL 16701339 T PL16701339 T PL 16701339T PL 3247791 T3 PL3247791 T3 PL 3247791T3
Authority
PL
Poland
Prior art keywords
universal
nkt cells
nkt
cells
universal nkt
Prior art date
Application number
PL16701339.0T
Other languages
English (en)
Polish (pl)
Inventor
Sébastien WÄLCHLI
Else Marit INDERBERG
Gustav Gaudernack
Gunnar Kvalheim
Original Assignee
Oslo Universitetssykehus Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Universitetssykehus Hf filed Critical Oslo Universitetssykehus Hf
Publication of PL3247791T3 publication Critical patent/PL3247791T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/15Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4225Growth factors
    • A61K40/4229Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4244Enzymes
    • A61K40/4246Telomerase or [telomerase reverse transcriptase [TERT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4271Melanoma antigens
    • A61K40/4272Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28Expressing multiple CARs, TCRs or antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/99Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16701339.0T 2015-01-23 2016-01-22 Uniwersalne komórki nkt PL3247791T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (1)

Publication Number Publication Date
PL3247791T3 true PL3247791T3 (pl) 2022-09-05

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16701339.0T PL3247791T3 (pl) 2015-01-23 2016-01-22 Uniwersalne komórki nkt

Country Status (17)

Country Link
US (2) US11155786B2 (enExample)
EP (2) EP4095239A1 (enExample)
JP (1) JP6899333B2 (enExample)
KR (1) KR102479118B1 (enExample)
CN (1) CN107250351A (enExample)
AU (2) AU2016208475B2 (enExample)
CA (1) CA2973924C (enExample)
DK (1) DK3247791T3 (enExample)
EA (1) EA201791381A1 (enExample)
ES (1) ES2922231T3 (enExample)
GB (1) GB201501175D0 (enExample)
IL (1) IL253464B (enExample)
MX (1) MX390756B (enExample)
PL (1) PL3247791T3 (enExample)
PT (1) PT3247791T (enExample)
SG (1) SG11201705693XA (enExample)
WO (1) WO2016116601A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
WO2017192440A1 (en) * 2016-05-02 2017-11-09 Cerus Corporation Compositions and methods for improved nk cell therapies
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
EP3565565A4 (en) * 2017-01-04 2020-12-09 Nova Southeastern University NATURAL KILLER CELLS (NK) EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T-LYMPHOCYTE RECEPTOR COMPLEX (TCR), THEIR PRODUCTION METHODS AND THEIR THERAPEUTIC USE METHODS
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
JP7429222B2 (ja) * 2018-08-31 2024-02-07 アンヴェクティ エスアー Carの機能を評価する方法
WO2020191358A1 (en) * 2019-03-20 2020-09-24 Bluebird Bio, Inc. Adoptive cell therapy
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
US12084685B2 (en) 2019-07-29 2024-09-10 Massaachusetts Institute Of Technology Synthetic hydrogels for organogenesis
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
IL301543A (en) 2020-09-24 2023-05-01 Medigene Immunotherapies Gmbh Prame specific t cell receptors and uses thereof
TW202233831A (zh) * 2020-11-03 2022-09-01 中國大陸商杭州啟函生物科技有限公司 增強免疫療法的系統和方法
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
EP4404956A1 (en) 2021-09-21 2024-07-31 Oslo Universitetssykehus HF Binding proteins for terminal deoxynucleotidyl transferase (tdt)
TW202325844A (zh) * 2021-11-03 2023-07-01 中國大陸商杭州啟函生物科技有限公司 增強免疫療法的系統和方法
JP2025524005A (ja) * 2022-07-22 2025-07-25 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 養子免疫療法のための亢進された機能を有するcd3発現ナチュラルキラー細胞
WO2024261045A1 (en) 2023-06-20 2024-12-26 Zelluna Immunotherapy As Methods of enhancing or modifying nk cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
EP1007630B1 (en) 1997-04-30 2006-04-19 Hans Klingemann Natural killer cell lines and methods of use
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
AU2002351239A1 (en) 2001-12-04 2003-06-17 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
US7618817B2 (en) * 2004-07-10 2009-11-17 Fox Chase Cancer Center Genetically modified human natural killer cell lines
WO2006050270A2 (en) * 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US10247731B2 (en) * 2012-02-22 2019-04-02 Verik Bio, Inc. System for immunotherapy targeting tumor propagation and progression
EP2893003B1 (en) 2012-09-04 2021-03-31 Inven2 AS Selective and controlled expansion of educated nk cells
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
JP2016511636A (ja) 2013-02-04 2016-04-21 ロジャー ウィリアムズ メディカル センターRoger Williams Medical Center 消化管間質腫瘍(gist)を治療する方法及び組成物
JP6425301B2 (ja) * 2014-05-29 2018-11-21 国立大学法人富山大学 Tcrの細胞傷害活性誘導能を評価するためのnk細胞株、およびその作製方法
KR20170018450A (ko) 2014-06-18 2017-02-17 케모테라포이티쉐스 포르슝스인스티투트 게오르크-스파이어-하우스 세포 치료제로서의 car-발현 nk-92 세포
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine

Also Published As

Publication number Publication date
IL253464B (en) 2022-04-01
AU2016208475B2 (en) 2021-10-14
EA201791381A1 (ru) 2018-02-28
US20180010097A1 (en) 2018-01-11
EP4095239A1 (en) 2022-11-30
NZ733855A (en) 2023-10-27
DK3247791T3 (da) 2022-07-11
IL253464A0 (en) 2017-09-28
AU2022200126A1 (en) 2022-02-10
BR112017015631A2 (pt) 2018-03-13
PT3247791T (pt) 2022-07-20
JP2018512047A (ja) 2018-05-10
CN107250351A (zh) 2017-10-13
CA2973924A1 (en) 2016-07-28
CA2973924C (en) 2024-06-04
US20220127574A1 (en) 2022-04-28
EP3247791A1 (en) 2017-11-29
ES2922231T3 (es) 2022-09-12
EP3247791B1 (en) 2022-05-04
AU2016208475A1 (en) 2017-08-03
MX390756B (es) 2025-03-04
KR20170121178A (ko) 2017-11-01
US11155786B2 (en) 2021-10-26
WO2016116601A1 (en) 2016-07-28
JP6899333B2 (ja) 2021-07-07
GB201501175D0 (en) 2015-03-11
KR102479118B1 (ko) 2022-12-16
MX2017009459A (es) 2018-04-11
SG11201705693XA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
PL3247791T3 (pl) Uniwersalne komórki nkt
KR102034727B9 (ko) 배터리 모듈
HUE046262T2 (hu) Sejt
EP3858365C0 (en) T CAR CELLS OPTIMIZED WITH GOLD
PL3288830T3 (pl) Jednostka nadzoru
DK3356188T3 (da) Batterisystem
PL3118311T3 (pl) Antysensowny kwas nukleinowy
PL3509156T3 (pl) Roztwór elektrolitu
DK3341303T3 (da) Blisterpakning
PL3547392T3 (pl) Akumulator
DK3766582T3 (da) Cellekultur
DK3526827T3 (da) Batterienhed
EP3341117C0 (en) Reactor
DE112015003671A5 (de) Befeuchter
EP3465799A4 (en) BATTERY CONNECTOR
EP3309797A4 (en) SOLID ELECTROLYTE
EP3509104A4 (en) BETAVOLTAIC BATTERY
UA30460S (uk) Акумуляторна батарея
ES1141181Y (es) Envase con abrefacil incorporado
UA34266S (uk) Акумуляторна батарея
TH1601003330A (th) เซลล์หุ่นยนต์
FI20155407A7 (fi) Akkujärjestelmä
UA35361S (uk) Акумуляторна батарея
UA35362S (uk) Акумуляторна батарея
UA35580S (uk) Акумуляторна батарея